CJC-1295 + Ipamorelin
Nighttime GH-pulse support for recovery and lean mass. Needs a working pituitary.
GHRH analogue + GH secretagogue (ghrelin-receptor agonist)
Sermorelin was previously an FDA-approved GHRH analogue (later discontinued as a brand). Tesamorelin is FDA-approved for HIV-associated lipodystrophy. CJC-1295 and ipamorelin used in clinics are typically compounded / research peptides, not approved GH-replacement drugs.
Dual-pathway stimulation of physiologic GH pulses: a GHRH analogue (CJC-1295 no-DAC / Mod GRF 1-29 or sermorelin) plus a ghrelin-receptor agonist (ipamorelin preferred in ISSCA for selectivity). Requires a working pituitary. Benefits accrue over 8 to 12 weeks. Night / empty-stomach timing is emphasized.
Common-practice ranges, not a personal dose
Quick-reference combo (Vol 1 Ch.1)
CJC-1295 + Ipamorelin 200 mcg + 300 mcg nightly.
VOL1 · Chapter 1 · p.12
CJC-1295 without DAC (Vol 1 Ch.8)
100 to 300 μg per injection, 2 to 3 times weekly, before bed or 2 to 3 hours post-meal. Preferred for pulsatile pattern.
VOL1 · Chapter 8 · p.99
CJC-1295 with DAC (Vol 1 Ch.8)
1 to 2 mg once weekly. More convenient, less physiologic, faster desensitization risk. Vol 1 Ch.9 lists 2 to 3 mg weekly.
VOL1 · Chapters 8 to 9 · p.100, 113
Ipamorelin (Vol 1 Ch.8)
200 to 300 μg once daily before bed, 30 to 60 minutes before sleep. Selective, fewer side effects.
VOL1 · Chapter 8 · p.100
Gold-standard combination (Vol 1 Ch.8)
CJC-1295 no-DAC 100 to 200 μg + ipamorelin 200 to 300 μg together before bed, 5 days/week. Cycle 12 weeks on / 4 weeks off.
VOL1 · Chapter 8 · p.101
Sermorelin (Vol 1 Ch.9)
200 to 500 μg SC before bed, 5 to 6 nights weekly, empty stomach, 3 to 6 month cycles.
VOL1 · Chapter 9 · p.112
Mod GRF 1-29 (Vol 1 Ch.9)
100 to 300 μg, 1 to 3 times daily on empty stomach (pre-meal, post-workout, or bedtime).
VOL1 · Chapter 9 · p.113
Hexarelin (advanced only)
Vol 1: 100 to 200 μg 1 to 2x daily with mandatory cycling. Vol 2: 100 to 200 μg once daily max, pre-sleep only, ≤4 week cycles. Highest desensitization risk.
VOL1+VOL2 · Vol 1 Ch.8; Vol 2 Ch.8 · p.100; 59 to 60
Tesamorelin (labeled / arsenal)
2 mg nightly in the Vol 1 quick-reference for visceral fat / metabolic enhancement. This is the FDA-labeled analogue family for HIV lipodystrophy, prescribe only to label.
VOL1 · Chapter 1 · p.12
Vol 2 preferred clinic pattern
CJC-1295 no-DAC 100 to 200 mcg SC 1 to 2x daily, pre-sleep mandatory. Ipamorelin 100 to 300 mcg SC 1 to 3x daily, pre-sleep ± post-training. Standard restoration protocol: CJC 100 mcg + ipamorelin 200 mcg pre-sleep for 8 to 12 weeks.
VOL2 · Chapter 8 · p.59 to 60
Cycle / washout. Vol 1 gold standard 12 on / 4 off. Vol 2 standard 8 to 12 weeks, washout 4 to 6 weeks. Hexarelin ≤4 weeks. Continuous use without breaks → receptor fatigue.
- Active cancer (IGF-1 / tumor-growth theory)
- Severe poorly controlled diabetes
- Pregnancy / lactation
- Pituitary failure (secretagogues cannot replace an absent axis)
- Patients wanting overnight 'HGH bodybuilding' results
Sources: Vol 1 Ch.1 p.12 · Vol 1 Ch.8 to 9 pp.96 to 119 · Vol 2 Ch.8 pp.59 to 60
